S&P 500   4,269.63 (+1.15%)
DOW   33,540.51 (+1.45%)
QQQ   353.79 (+0.51%)
AAPL   180.08 (+-0.01%)
MSFT   334.14 (+0.47%)
META   273.36 (+0.28%)
GOOGL   124.43 (+0.57%)
AMZN   125.45 (+2.18%)
TSLA   214.44 (+3.33%)
NVDA   396.17 (-0.38%)
NIO   7.73 (+2.52%)
BABA   85.29 (+2.76%)
AMD   118.97 (-0.42%)
T   14.99 (-5.19%)
F   12.43 (+2.64%)
MU   68.79 (-0.43%)
CGC   0.84 (+1.03%)
GE   104.81 (+0.13%)
DIS   90.15 (+1.76%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.15 (+1.74%)
NFLX   400.04 (-0.77%)
S&P 500   4,269.63 (+1.15%)
DOW   33,540.51 (+1.45%)
QQQ   353.79 (+0.51%)
AAPL   180.08 (+-0.01%)
MSFT   334.14 (+0.47%)
META   273.36 (+0.28%)
GOOGL   124.43 (+0.57%)
AMZN   125.45 (+2.18%)
TSLA   214.44 (+3.33%)
NVDA   396.17 (-0.38%)
NIO   7.73 (+2.52%)
BABA   85.29 (+2.76%)
AMD   118.97 (-0.42%)
T   14.99 (-5.19%)
F   12.43 (+2.64%)
MU   68.79 (-0.43%)
CGC   0.84 (+1.03%)
GE   104.81 (+0.13%)
DIS   90.15 (+1.76%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.15 (+1.74%)
NFLX   400.04 (-0.77%)
S&P 500   4,269.63 (+1.15%)
DOW   33,540.51 (+1.45%)
QQQ   353.79 (+0.51%)
AAPL   180.08 (+-0.01%)
MSFT   334.14 (+0.47%)
META   273.36 (+0.28%)
GOOGL   124.43 (+0.57%)
AMZN   125.45 (+2.18%)
TSLA   214.44 (+3.33%)
NVDA   396.17 (-0.38%)
NIO   7.73 (+2.52%)
BABA   85.29 (+2.76%)
AMD   118.97 (-0.42%)
T   14.99 (-5.19%)
F   12.43 (+2.64%)
MU   68.79 (-0.43%)
CGC   0.84 (+1.03%)
GE   104.81 (+0.13%)
DIS   90.15 (+1.76%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.15 (+1.74%)
NFLX   400.04 (-0.77%)
S&P 500   4,269.63 (+1.15%)
DOW   33,540.51 (+1.45%)
QQQ   353.79 (+0.51%)
AAPL   180.08 (+-0.01%)
MSFT   334.14 (+0.47%)
META   273.36 (+0.28%)
GOOGL   124.43 (+0.57%)
AMZN   125.45 (+2.18%)
TSLA   214.44 (+3.33%)
NVDA   396.17 (-0.38%)
NIO   7.73 (+2.52%)
BABA   85.29 (+2.76%)
AMD   118.97 (-0.42%)
T   14.99 (-5.19%)
F   12.43 (+2.64%)
MU   68.79 (-0.43%)
CGC   0.84 (+1.03%)
GE   104.81 (+0.13%)
DIS   90.15 (+1.76%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.15 (+1.74%)
NFLX   400.04 (-0.77%)
NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast, Price & News

$7.30
+0.25 (+3.55%)
(As of 10:40 AM ET)
Compare
Today's Range
$7.12
$7.31
50-Day Range
$6.19
$8.83
52-Week Range
$5.95
$13.21
Volume
298,494 shs
Average Volume
940,265 shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.80

Adaptive Biotechnologies MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
90.6% Upside
$13.80 Price Target
Short Interest
Bearish
4.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.62mentions of Adaptive Biotechnologies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$354,339 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.20) to ($0.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

795th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

103rd out of 330 stocks


ADPT stock logo

About Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADPT Stock News Headlines

Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Adaptive Biotechnologies Q1 Loss decreases, but misses estimates
See More Headlines

ADPT Price History

ADPT Company Calendar

Last Earnings
5/03/2023
Today
6/02/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADPT
Employees
858
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$13.80
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+95.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-200,190,000.00
Net Margins
-105.87%
Pretax Margin
-105.93%

Debt

Sales & Book Value

Annual Sales
$185.31 million
Book Value
$2.94 per share

Miscellaneous

Free Float
138,250,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
1.18

Social Links


Key Executives

  • Chad RobinsChad Robins
    Chairman & Chief Executive Officer
  • Julie RubinsteinJulie Rubinstein
    President & Chief Operating Officer
  • Tycho W. Peterson
    Chief Financial Officer
  • Harlan RobinsHarlan Robins
    Chief Scientific Officer
  • Zhou Yi
    Chief Technical Officer













ADPT Stock - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares.
View ADPT analyst ratings
or view top-rated stocks.

What is Adaptive Biotechnologies' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month price targets for Adaptive Biotechnologies' shares. Their ADPT share price forecasts range from $7.00 to $17.00. On average, they anticipate the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for ADPT
or view top-rated stocks among Wall Street analysts.

How have ADPT shares performed in 2023?

Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT stock has decreased by 7.7% and is now trading at $7.05.
View the best growth stocks for 2023 here
.

Are investors shorting Adaptive Biotechnologies?

Adaptive Biotechnologies saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,630,000 shares, an increase of 8.9% from the April 30th total of 6,090,000 shares. Based on an average daily volume of 856,600 shares, the short-interest ratio is presently 7.7 days. Currently, 4.8% of the shares of the stock are sold short.
View Adaptive Biotechnologies' Short Interest
.

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our ADPT earnings forecast
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its earnings results on Wednesday, May, 3rd. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.06. The firm earned $37.65 million during the quarter, compared to analysts' expectations of $36.81 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 41.21% and a negative net margin of 105.87%. The business's quarterly revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.44) EPS.

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$215.00 million, compared to the consensus revenue estimate of $208.52 million.

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.15%), ARK Investment Management LLC (6.43%), Sumitomo Mitsui Trust Holdings Inc. (3.72%), Nikko Asset Management Americas Inc. (3.72%), State Street Corp (1.78%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Susan Bobulsky.
View institutional ownership trends
.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $7.05.

How much money does Adaptive Biotechnologies make?

Adaptive Biotechnologies (NASDAQ:ADPT) has a market capitalization of $1.02 billion and generates $185.31 million in revenue each year. The company earns $-200,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Adaptive Biotechnologies have?

The company employs 858 workers across the globe.

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The official website for the company is www.constructionpartners.net. The company can be reached via phone at (206) 659-0067, via email at investors@adaptivebiotech.com, or via fax at 206-659-0667.

This page (NASDAQ:ADPT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -